Results 21 to 30 of about 253,625 (250)

Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States. [PDF]

Prostate Cancer Prostatic Dis
The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) has evolved since radium-223 (Ra-223) was approved in the United States (2013).
Raval AD, Zhang Y, Korn M, Constantinovici N, McKay RR.   +4 more
europepmc   +2 more sources

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment [PDF]

Diagnostics, 2023
(1) Background: Prostate cancer is the second most common cancer in men, with androgen suppression as the standard treatment. Despite initially responding to castration, most metastatic prostate cancer patients eventually experience progression. In these
Elisabet Cantó, Georgia Anguera, Natalia Jiménez, Begoña Mellado, Ona Ramírez, Anais Mariscal, Pablo Maroto, Silvia Vidal   +7 more
doaj   +2 more sources

Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety Study [PDF]

Oncology and Therapy
Introduction Radium-223 is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, without visceral metastases, who progress after at least (≥) two lines of or are ineligible for other systemic ...
Rachel Weinrib, Joan Fortuny, David Martinez, Bianca Kollhorst, Ulrike Haug, Astrid Kousholt, Vera Ehrenstein, Peter Iversen, Jann Mortensen, Dianne Bosch, Malou Kuppen, Federica Pisa, Zdravko Vassilev   +12 more
doaj   +2 more sources

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial. [PDF]

J Clin Oncol
PURPOSE Randomized clinical trials (RCTs) have shown progression-free survival (PFS) benefits of metastasis-directed therapy (MDT) without androgen deprivation therapy for oligometastatic castration-sensitive prostate cancer (omCSPC).
Wang JH, Sherry AD, Bazyar S, Sutera P, Radwan N, Phillips RM, Deek MP, Lu J, Dipasquale S, Deville C, DeWeese TL, Song DY, Wang H, Hobbs RF, Malek R, Dudley SA, Greco SC, Antonarakis ES, Marshall CH, Denmeade S, Paller CJ, Carducci MA, Pienta KJ, Oz OK, Ramotar M, Leenstra JL, Park SS, Abramowitz MC, Desai N, Berlin A, Stish BJ, Tang C, Tran PT, Kiess AP.   +33 more
europepmc   +2 more sources

Ocular complications with the use of radium-223: a case series [PDF]

Radiation Oncology, 2022
Background Radium-223 is used for the treatment of osseous metastases in castrate-resistant prostate cancer, and has been shown to increase time to the first skeletal-related event, reduce the rate of hospitalization, and improve quality of life.
Julie R. Bloom, Alexandra G. Castillejos, Brianna Jones, Nimesh Patel, Barry S. Rosenstein, Richard G. Stock   +5 more
doaj   +2 more sources

ATM inhibition increases the anti-tumor efficacy of radium-223 (Ra-223) against prostate cancer bone metastasis in preclinical models. [PDF]

JBMR Plus
Prostate cancer bone metastases are commonly treated with radium-223 (Ra-223); however, patients ultimately experience relapse. These metastases are currently incurable and there is an unmet need to improve the efficacy of Ra-223 treatment regimens.
Lefley DV, Jones CG, Zhou J, Bryant HE, Collis SJ, Down JM, Brown JE, Ottewell PD.   +7 more
europepmc   +2 more sources

Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer [PDF]

Current Oncology
Introduction: Radium-223 dichloride (radium-223) is a bone-targeting radioisotope therapy that aids in the survival of patients with metastatic castration-resistant prostate cancer (mCRPC) to bones.
Colleen Mackenzie, Jasna Deluce, Morgan Black, Emma Churchman, Eric Winquist, Scott Ernst, David T. Laidley, Matthew Parezanovic, Kylea Potvin, Ricardo Fernandes   +9 more
doaj   +2 more sources

Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study

Therapeutic Advances in Medical Oncology, 2021
Background: Radium-223 and enzalutamide are approved agents for patients with metastatic castration-resistant prostate cancer (mCRPC). Combining radium-223 and enzalutamide to improve outcomes is of clinical interest due to their differing modes of ...
Raymond S Mcdermott, John Greene, Anne-Marie Baird   +2 more
exaly   +2 more sources

Post-marketing surveillance of radium-223 chloride in Japanese patients with castration-resistant prostate cancer with bone metastasis-final analysis of 3-year extended follow-up focusing on bone fractures. [PDF]

Int J Clin Oncol
A post-marketing surveillance (PMS) study was conducted in Japan to assess real-world outcomes with radium-223 treatment in men with metastatic castration-resistant prostate cancer (mCRPC).
Masumori N, Hosono M, Takahashi S, Kakehi Y, Uemura H, Sunaya T, Shimotsumagari K, Matsuba Y, Adachi M, Kakiuchi H, Kinuya S.   +10 more
europepmc   +2 more sources

Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data [PDF]

Medicina, 2019
Background and Objective: Radium-223 dichloride (Xofigo®) is a calcium mimetic agent approved for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. This targeted,
Theodoros G. Soldatos, Ioannis Iakovou, Christos Sachpekidis   +2 more
doaj   +2 more sources